Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02532452 · ClinicalTrials.gov registry record · Phase 2
Third Party Viral Specific T-cells (VSTs)
A Phase 2 study of Viral Infection and Viral Reactivation, sponsored by Children's Hospital Medical Center, Cincinnati.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 750
- Enrollment target
- 4
- Study locations
NCT02532452 is a Phase 2 study of Viral Infection and Viral Reactivation that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 750 participants, above the 161-participant average among 11 other Viral Infection trials with a reported enrollment target (366% higher). The trial reports 4 study locations across 1 state.
The verdict
NCT02532452, a Phase 2 study of Viral Infection and Viral Reactivation, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 750 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to demonstrate that viral specific T-cells (a type of white blood cell) can be generated from an unrelated donor and given safely to patients with viral infections.
Conditions Studied
Interventions
- BIOLOGICAL Viral Specific VST Infusion
Study Locations (4)
Ohio
- Akron Children's Hospital - Akron
- University of Cincinnati Medical Center - Cincinnati
- Cincinnati Children's Hospital Medical Center - Cincinnati
- The Ohio State University Wexner Medical Center - James Cancer Hospital - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2015-09-02 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02532452
The ClinicalTrials.gov registry entry for NCT02532452 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 750 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 161-participant average among 11 other Viral Infection trials with a reported enrollment target (366% higher). The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Viral Infection appearing as the primary indexed condition, and to 1 intervention - of which Viral Specific VST Infusion is the first listed.
NCT02532452 reports 4 study locations spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT02532452 about?
NCT02532452 is a clinical study titled "Third Party Viral Specific T-cells (VSTs)". The purpose of this study is to demonstrate that viral specific T-cells (a type of white blood cell) can be generated from an unrelated donor and given safely to patients with viral infections.
What is the current status of trial NCT02532452?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 750 participants. The study started on 2015-09-02. Estimated completion is 2027-12.
What conditions does trial NCT02532452 study?
This clinical trial studies the following conditions: Viral Infection, Viral Reactivation, Infection in an Immunocompromised Host.
What interventions are being tested in trial NCT02532452?
The interventions under investigation include: Viral Specific VST Infusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT02532452?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02532452 being conducted?
This trial has 4 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Viral Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells for Viral Infections After Stem Cell Transplant
RECRUITING · Phase 2
-
Viral Specific T-cells for Treatment of Viral Infections After Solid Organ Transplant
ACTIVE NOT RECRUITING · Phase 2
-
Smell Changes & Efficacy of Nasal Theophylline
COMPLETED · Phase 2
-
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
RECRUITING · Phase 1
-
Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis
RECRUITING · Phase 1
-
School Inner City Air Study
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.